We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Croda International Plc | LSE:CRDA | London | Ordinary Share | GB00BJFFLV09 | ORD 10.609756P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -35.00 | -0.77% | 4,497.00 | 439,130 | 16:35:27 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 4,477.00 | 4,480.00 | 4,529.00 | 4,463.00 | 4,504.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Chemicals & Chem Preps, Nec | 2.09B | 649.3M | 4.6500 | 9.63 | 6.25B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 18:45:06 | O | 3,741 | 4,496.33 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 28/11/2023 | 09:35 | UKREG | Croda International PLC Director/PDMR Shareholding |
| 24/11/2023 | 11:33 | UKREG | Croda International PLC Holding(s) in Company |
| 14/11/2023 | 09:40 | UKREG | Croda International PLC Director/PDMR Shareholding |
| 19/10/2023 | 10:19 | UKREG | Croda International PLC Holding(s) in Company |
| 19/10/2023 | 09:34 | UKREG | Croda International PLC Director/PDMR Shareholding |
| 12/10/2023 | 10:46 | UKREG | Croda International PLC Director/PDMR Shareholding |
| 09/10/2023 | 07:30 | ALNC |  TOP NEWS: Croda slashes full-year profit expectations amid weak demand |
| 09/10/2023 | 06:00 | UKREG | Croda International PLC Third Quarter Trading Update |
| 06/10/2023 | 15:12 | UKREG | Croda International PLC Director/PDMR Shareholding |
| 05/10/2023 | 07:53 | UKREG | Croda International PLC Holding(s) in Company |
Croda (CRDA) Share Charts1 Year Croda Chart |
|
1 Month Croda Chart |
Intraday Croda Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/11/2023 | 14:44 | CRODA | 308 |
| 24/7/2018 | 21:20 | Croda Intl (CRDA) One to Watch on Wednesday | - |
| 23/7/2014 | 14:31 | TipTv analyses the prospects of Croda International PLC (CRDA) | - |
| 25/7/2012 | 19:28 | CRODA BACK TO Ј7 | 253 |
| 05/2/2007 | 14:35 | Strong Outlook | 98 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2023-11-28 17:30:39 | 4,477.37 | 161 | 7,208.57 | O |
| 2023-11-28 17:27:09 | 4,497.00 | 5,857 | 263,389.29 | O |
| 2023-11-28 17:24:04 | 4,524.05 | 21 | 950.05 | O |
| 2023-11-28 17:21:52 | 4,471.94 | 191 | 8,541.41 | O |
| 2023-11-28 17:21:51 | 4,469.74 | 43 | 1,921.99 | O |
| Top Posts |
|---|
Posted at 28/11/2023 08:20 by Croda Daily Update Croda International Plc is listed in the Chemicals & Chem Preps, Nec sector of the London Stock Exchange with ticker CRDA. The last closing price for Croda was 4,532p.Croda currently has 139,635,400 shares in issue. The market capitalisation of Croda is £6,254,269,566. Croda has a price to earnings ratio (PE ratio) of 9.63. This morning CRDA shares opened at 4,504p |
Posted at 19/9/2023 15:27 by commuter10 This gives real cause for concern as share price has now halved from Mid-2021 levels.Is this a hold or sell share now do we think? |
Posted at 19/6/2023 16:34 by steeplejack And another one…JPMorgan Cazenove slashed its price target on Croda to 5,000p from 6,200p and retained its 'underweight' rating. The bank said the new price target is based on around 22x 2025 estimate price-to-earnings, with the target multiple still reflecting an optimistic premium to last 10years. JPM said the company's recent earnings reset by management reduces near-term risks, although the visibility on 2H23/2024 earnings recovery remains low, in the bank's opinion. "Further, fundamentally, a pronounced earnings decline in 2023 with an implied 5-year organic EBIT compound annual growth rate of circa 2% and around 8-9% points decline in post-tax ROIC over this period (due to a step-up in M&A and to a lesser extent organic growth capex) do not justify the market expectations of a structural substantial step-up in organic growth and as a result substantial re-rating of the shares seen over the past four years, in our opinion," it said. JPM's lowered FY23/24 adjusted earnings per share estimates are 5%/11% below post-warning company consensus. "Some of the current earnings pressure - 2023E adjusted EBIT likely to be down 15% year-on-year ex Covid-19 vaccines related earnings - reflect the sector-wide cyclical downturn and inventory destocking trends," it said. "However, the company has likely also continued to lose material market share in its consumer care business, in which 2023e volumes are likely to be around 15% below 2018 levels." |
Posted at 15/6/2023 20:55 by steeplejack Berenberg cut its price target on Croda as it trimmed estimates a week after the specialty chemicals firm warned on profits, but maintained its 'buy' recommendation.The bank, which reduced the price target to £66 from £80 ,said big profit warnings from Croda are rare - as are good entry points. “The last time the company issued a trading update remotely as bearish as the one of 9 June 2023 was on 24 June 2014, when industrials were a larger part of mix," it noted. “The smooth journey for Croda over the difficult subsequent period for the chemicals sector - one of Chinese overcapacity, then the Covid-19 pandemic, then the European energy crisis - speaks for the robustness of the business. "The recovery of shares,following the 2014 warning, suggests it is a good idea to buy on weakness. We understand that US order books show some signs of improvement, and survey data (see our consumer team's China review) point to a solid outlook for China. "Europe is not yet at the end of squeeze on discretionary incomes, but volumes should improve by the start of FY24." Berenberg said the 20% cuts to its earnings per share estimates reflect lower sales volumes and prices in consumer care and crop protection, in addition to lower prices for by-product sales in the industrial specialities segment. |
Posted at 07/6/2023 07:19 by steeplejack Goldman Sachs cuts Croda International to 'neutral' (buy) - price target 7,200 (8,700) pence |
Posted at 06/4/2023 16:48 by wad collector Somebody paid 65.50 for 200k shares this afternoon, woke the price up a bit. Those heady days of £100 back in 2021 look a long way away still though. |
Posted at 01/3/2023 08:16 by steeplejack The Directors are recommending a final dividend of 61.0p per share amounting to a total of GBP85.1m in respect of the financial year ended 31 December 2022. Subject to shareholder approval, the dividend will be paid on 26 May 2023 to shareholders registered on 28 April 2023. The total proposed dividend for the year ended 31 December 2022 will be 108.0p per share amounting to GBP150.7m. |
Posted at 18/2/2022 16:43 by mercury123 It seems to me that either there is some really bad news out there (unlikely IMHO) or those who are shorting are making a last heave to push the price down before they have to buy back which I will be very surprised if they don't do before results on 1st March.The only real unknown is the Ukraine situation which could drive everything down. We still have only one broker recommending a sell, 3 strong buys and 10 holds. So I'm hanging on. Good luck all (unless you're shorting..). |
Posted at 08/2/2022 18:57 by riskonricky Current price is abt 30 years worth of current earnings |
Posted at 23/12/2021 15:48 by philanderer Croda: Vaccine boost offsets industrial saleThere was some disappointment at the decision of chemicals specialist Croda (CRDA) to sell its bio-based industrial business, but the stock remains well ahead this year thanks to its vaccine exposure, according to Hargreaves Lansdown. The group reported the sale of its bio-based industrial business to US firm Cargill Velocity for £778m following a review of this part of the business. The price tag has, however, disappointed some investors, as the shares eased 0.4% to £99.42. Analyst Susannah Streeter said it was still one of the FTSE 100’s best performers in 2021, up 48% over the year thanks to strong first-half results and full-year profits forecast to beat earlier expectations. ‘The extent to which Croda is benefiting from the ongoing vaccine boom has become clear over recent months and it’s down to its investment in innovative technologies,’ she said. ‘It supplies lipid nanoparticles for Pfizer’s mRNA technology and given the demand for booster jabs, that area of life sciences is bounding along.’ Streeter said even when vaccine demand wanes there will still be demand for ‘a broader range of use of its products in medical treatments like oncology’. ‘Recovery in consumer markets has also helped its personal care sector which focuses on ingredients for skin, hair, and cosmetic products and the focus on sustainability should help drive sales among an increasingly eco-conscious customer base,’ said Streeter. citywire.com |
Posted at 08/12/2021 16:52 by wad collector Croda International (CRDA)Citigroup Buy 9,500.00p 9,500.00p Reiteration I love brokers and updates, they put as Buy with a £9.50 target price and yet the current price is £10.30! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
